Selected research
Market Structure
Global Peptide and Oligonucleotide Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Peptide and Oligonucleotide Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Peptide and Oligonucleotide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Peptide and Oligonucleotide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Peptide and Oligonucleotide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Peptide and Oligonucleotide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Peptide and Oligonucleotide Drugs include Takeda, Sanofi, Novartis, Roche, Lilly, SciClone Pharmaceuticals, Sarepta Therapeutics, Nippon Shinyaku and Moderna, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Peptide and Oligonucleotide Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Peptide and Oligonucleotide Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Peptide and Oligonucleotide Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peptide and Oligonucleotide Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Peptide and Oligonucleotide Drugs Segment by Company
Takeda
Sanofi
Novartis
Roche
Lilly
SciClone Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
Moderna
MiNA Therapeutics
Merck Serono
Ipsen PHarma Biotech
Ionis
Ferring Pharmaceuticals
BioNTech
AstraZeneca
Asahi Kasei
Alnylam
Peptide and Oligonucleotide Drugs Segment by Type
Oligonucleotide Drugs
Peptide Drugs
Peptide and Oligonucleotide Drugs Segment by Application
Oncology Drugs
Digestive system Drugs
Immunomodulatory Drugs
Bone and Connective Tissue Types
Other
Peptide and Oligonucleotide Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide and Oligonucleotide Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide and Oligonucleotide Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide and Oligonucleotide Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Peptide and Oligonucleotide Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide and Oligonucleotide Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Peptide and Oligonucleotide Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Peptide and Oligonucleotide Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
List of Tables
Table 1. Peptide and Oligonucleotide Drugs Industry Trends
Table 2. Peptide and Oligonucleotide Drugs Industry Drivers
Table 3. Peptide and Oligonucleotide Drugs Industry Opportunities and Challenges
Table 4. Peptide and Oligonucleotide Drugs Industry Restraints
Table 5. Global Peptide and Oligonucleotide Drugs Revenue by Manufacturers (US$ Million) & (2021-2026)
Table 6. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Manufacturers (2021-2026)
Table 7. Global Peptide and Oligonucleotide Drugs Sales by Manufacturers (K Units) & (2021-2026)
Table 8. Global Peptide and Oligonucleotide Drugs Sales Market Share by Manufacturers
Table 9. Global Peptide and Oligonucleotide Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026)
Table 10. Global Peptide and Oligonucleotide Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
Table 11. Global Peptide and Oligonucleotide Drugs Key Manufacturers Manufacturing Sites & Headquarters
Table 12. Global Peptide and Oligonucleotide Drugs Manufacturers, Product Type & Application
Table 13. Global Peptide and Oligonucleotide Drugs Manufacturers Establishment Date
Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Global Peptide and Oligonucleotide Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
Table 16. Major Manufacturers of Oligonucleotide Drugs
Table 17. Major Manufacturers of Peptide Drugs
Table 18. Global Peptide and Oligonucleotide Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units)
Table 19. Global Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (K Units)
Table 20. Global Peptide and Oligonucleotide Drugs Sales by Type (2027-2032) & (K Units)
Table 21. Global Peptide and Oligonucleotide Drugs Sales Market Share by Type (2021-2026)
Table 22. Global Peptide and Oligonucleotide Drugs Sales Market Share by Type (2027-2032)
Table 23. Global Peptide and Oligonucleotide Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units)
Table 24. Global Peptide and Oligonucleotide Drugs Revenue by Type (2021-2026) & (K Units)
Table 25. Global Peptide and Oligonucleotide Drugs Revenue by Type (2027-2032) & (K Units)
Table 26. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Type (2021-2026)
Table 27. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Type (2027-2032)
Table 28. Major Manufacturers of Oncology Drugs
Table 29. Major Manufacturers of Digestive system Drugs
Table 30. Major Manufacturers of Immunomodulatory Drugs
Table 31. Major Manufacturers of Bone and Connective Tissue Types
Table 32. Major Manufacturers of Other
Table 33. Global Peptide and Oligonucleotide Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units)
Table 34. Global Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (K Units)
Table 35. Global Peptide and Oligonucleotide Drugs Sales by Application (2027-2032) & (K Units)
Table 36. Global Peptide and Oligonucleotide Drugs Sales Market Share by Application (2021-2026)
Table 37. Global Peptide and Oligonucleotide Drugs Sales Market Share by Application (2027-2032)
Table 38. Global Peptide and Oligonucleotide Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units)
Table 39. Global Peptide and Oligonucleotide Drugs Revenue by Application (2021-2026) & (K Units)
Table 40. Global Peptide and Oligonucleotide Drugs Revenue by Application (2027-2032) & (K Units)
Table 41. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Application (2021-2026)
Table 42. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Application (2027-2032)
Table 43. Global Peptide and Oligonucleotide Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units)
Table 44. Global Peptide and Oligonucleotide Drugs Sales by Region (2021-2026) & (K Units)
Table 45. Global Peptide and Oligonucleotide Drugs Sales Market Share by Region (2021-2026)
Table 46. Global Peptide and Oligonucleotide Drugs Sales Forecasted by Region (2027-2032) & (K Units)
Table 47. Global Peptide and Oligonucleotide Drugs Sales Forecasted Market Share by Region (2027-2032)
Table 48. North America Peptide and Oligonucleotide Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 49. North America Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units)
Table 50. North America Peptide and Oligonucleotide Drugs Sales by Country (2027-2032) & (K Units)
Table 51. Europe Peptide and Oligonucleotide Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 52. Europe Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units)
Table 53. Europe Peptide and Oligonucleotide Drugs Sales by Country (2027-2032) & (K Units)
Table 54. Asia Pacific Peptide and Oligonucleotide Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 55. Asia Pacific Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units)
Table 56. Asia Pacific Peptide and Oligonucleotide Drugs Sales by Country (2027-2032) & (K Units)
Table 57. South America, Middle East and Africa Peptide and Oligonucleotide Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 58. South America, Middle East and Africa Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units)
Table 59. South America, Middle East and Africa Peptide and Oligonucleotide Drugs Sales by Country (2027-2032) & (K Units)
Table 60. Global Peptide and Oligonucleotide Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 61. Global Peptide and Oligonucleotide Drugs Revenue by Region (2021-2026) & (US$ Million)
Table 62. Global Peptide and Oligonucleotide Drugs Revenue by Region (2027-2032) & (US$ Million)
Table 63. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Region (2021-2026)
Table 64. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Region (2027-2032)
Table 65. Takeda Company Information
Table 66. Takeda Business Overview
Table 67. Takeda Peptide and Oligonucleotide Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 68. Takeda Peptide and Oligonucleotide Drugs Product Portfolio
Table 69. Takeda Recent Development
Table 70. Sanofi Company Information
Table 71. Sanofi Business Overview
Table 72. Sanofi Peptide and Oligonucleotide Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 73. Sanofi Peptide and Oligonucleotide Drugs Product Portfolio
Table 74. Sanofi Recent Development
Table 75. Novartis Company Information
Table 76. Novartis Business Overview
Table 77. Novartis Peptide and Oligonucleotide Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 78. Novartis Peptide and Oligonucleotide Drugs Product Portfolio
Table 79. Novartis Recent Development
Table 80. Roche Company Information
Table 81. Roche Business Overview
Table 82. Roche Peptide and Oligonucleotide Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 83. Roche Peptide and Oligonucleotide Drugs Product Portfolio
Table 84. Roche Recent Development
Table 85. Lilly Company Information
Table 86. Lilly Business Overview
Table 87. Lilly Peptide and Oligonucleotide Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 88. Lilly Peptide and Oligonucleotide Drugs Product Portfolio
Table 89. Lilly Recent Development
Table 90. SciClone Pharmaceuticals Company Information
Table 91. SciClone Pharmaceuticals Business Overview
Table 92. SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 93. SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio
Table 94. SciClone Pharmaceuticals Recent Development
Table 95. Sarepta Therapeutics Company Information
Table 96. Sarepta Therapeutics Business Overview
Table 97. Sarepta Therapeutics Peptide and Oligonucleotide Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 98. Sarepta Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio
Table 99. Sarepta Therapeutics Recent Development
Table 100. Nippon Shinyaku Company Information
Table 101. Nippon Shinyaku Business Overview
Table 102. Nippon Shinyaku Peptide and Oligonucleotide Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 103. Nippon Shinyaku Peptide and Oligonucleotide Drugs Product Portfolio
Table 104. Nippon Shinyaku Recent Development
Table 105. Moderna Company Information
Table 106. Moderna Business Overview
Table 107. Moderna Peptide and Oligonucleotide Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 108. Moderna Peptide and Oligonucleotide Drugs Product Portfolio
Table 109. Moderna Recent Development
Table 110. MiNA Therapeutics Company Information
Table 111. MiNA Therapeutics Business Overview
Table 112. MiNA Therapeutics Peptide and Oligonucleotide Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 113. MiNA Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio
Table 114. MiNA Therapeutics Recent Development
Table 115. Merck Serono Company Information
Table 116. Merck Serono Business Overview
Table 117. Merck Serono Peptide and Oligonucleotide Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 118. Merck Serono Peptide and Oligonucleotide Drugs Product Portfolio
Table 119. Merck Serono Recent Development
Table 120. Ipsen PHarma Biotech Company Information
Table 121. Ipsen PHarma Biotech Business Overview
Table 122. Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 123. Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Product Portfolio
Table 124. Ipsen PHarma Biotech Recent Development
Table 125. Ionis Company Information
Table 126. Ionis Business Overview
Table 127. Ionis Peptide and Oligonucleotide Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 128. Ionis Peptide and Oligonucleotide Drugs Product Portfolio
Table 129. Ionis Recent Development
Table 130. Ferring Pharmaceuticals Company Information
Table 131. Ferring Pharmaceuticals Business Overview
Table 132. Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 133. Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio
Table 134. Ferring Pharmaceuticals Recent Development
Table 135. BioNTech Company Information
Table 136. BioNTech Business Overview
Table 137. BioNTech Peptide and Oligonucleotide Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 138. BioNTech Peptide and Oligonucleotide Drugs Product Portfolio
Table 139. BioNTech Recent Development
Table 140. AstraZeneca Company Information
Table 141. AstraZeneca Business Overview
Table 142. AstraZeneca Peptide and Oligonucleotide Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 143. AstraZeneca Peptide and Oligonucleotide Drugs Product Portfolio
Table 144. AstraZeneca Recent Development
Table 145. Asahi Kasei Company Information
Table 146. Asahi Kasei Business Overview
Table 147. Asahi Kasei Peptide and Oligonucleotide Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 148. Asahi Kasei Peptide and Oligonucleotide Drugs Product Portfolio
Table 149. Asahi Kasei Recent Development
Table 150. Alnylam Company Information
Table 151. Alnylam Business Overview
Table 152. Alnylam Peptide and Oligonucleotide Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 153. Alnylam Peptide and Oligonucleotide Drugs Product Portfolio
Table 154. Alnylam Recent Development
Table 155. Key Raw Materials
Table 156. Raw Materials Key Suppliers
Table 157. Peptide and Oligonucleotide Drugs Distributors List
Table 158. Peptide and Oligonucleotide Drugs Customers List
Table 159. Research Programs/Design for This Report
Table 160. Authors List of This Report
Table 161. Secondary Sources
Table 162. Primary Sources
List of Figures
Figure 1. Peptide and Oligonucleotide Drugs Product Image
Figure 2. Global Peptide and Oligonucleotide Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Peptide and Oligonucleotide Drugs Market Size (2021-2032) & (US$ Million)
Figure 4. Global Peptide and Oligonucleotide Drugs Sales (2021-2032) & (K Units)
Figure 5. Global Peptide and Oligonucleotide Drugs Average Price (US$/Unit) & (2021-2032)
Figure 6. Global Top 5 and 10 Peptide and Oligonucleotide Drugs Players Market Share by Revenue in 2025
Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 8. Oligonucleotide Drugs Image
Figure 9. Peptide Drugs Image
Figure 10. Global Peptide and Oligonucleotide Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 11. Global Peptide and Oligonucleotide Drugs Sales Market Share 2021 VS 2025 VS 2032
Figure 12. Global Peptide and Oligonucleotide Drugs Sales Market Share by Type (2021-2032)
Figure 13. Global Peptide and Oligonucleotide Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 14. Global Peptide and Oligonucleotide Drugs Revenue Market Share 2021 VS 2025 VS 2032
Figure 15. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Type (2021-2032)
Figure 16. Oncology Drugs Image
Figure 17. Digestive system Drugs Image
Figure 18. Immunomodulatory Drugs Image
Figure 19. Bone and Connective Tissue Types Image
Figure 20. Other Image
Figure 21. Global Peptide and Oligonucleotide Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 22. Global Peptide and Oligonucleotide Drugs Sales Market Share 2021 VS 2025 VS 2032
Figure 23. Global Peptide and Oligonucleotide Drugs Sales Market Share by Application (2021-2032)
Figure 24. Global Peptide and Oligonucleotide Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 25. Global Peptide and Oligonucleotide Drugs Revenue Market Share 2021 VS 2025 VS 2032
Figure 26. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Application (2021-2032)
Figure 27. North America Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 28. North America Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021-2032)
Figure 29. U.S. Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 30. Canada Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 31. Mexico Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 32. Europe Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 33. Europe Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021-2032)
Figure 34. Germany Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 35. France Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 36. U.K. Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 37. Italy Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 38. Netherlands Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 39. Asia Pacific Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 40. Asia Pacific Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021-2032)
Figure 41. China Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 42. Japan Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 43. South Korea Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 44. Southeast Asia Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 45. India Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 46. Australia Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 47. South America, Middle East and Africa Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 48. South America, Middle East and Africa Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021-2032)
Figure 49. Brazil Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 50. South Africa Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 51. Saudi Arabia Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 52. Turkey Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 53. Argentina Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 54. UAE Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 55. Egypt Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 56. Chile Peptide and Oligonucleotide Drugs Sales and Growth Rate (2021-2032) & (K Units)
Figure 57. Global Peptide and Oligonucleotide Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 58. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032
Figure 59. North America Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million)
Figure 60. North America Peptide and Oligonucleotide Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 61. Europe Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million)
Figure 62. Europe Peptide and Oligonucleotide Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 63. Asia-Pacific Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million)
Figure 64. Asia-Pacific Peptide and Oligonucleotide Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 65. South America, Middle East and Africa Peptide and Oligonucleotide Drugs Revenue (2021-2032) & (US$ Million)
Figure 66. South America, Middle East and Africa Peptide and Oligonucleotide Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 67. Peptide and Oligonucleotide Drugs Value Chain
Figure 68. Manufacturing Cost Structure
Figure 69. Peptide and Oligonucleotide Drugs Production Mode & Process
Figure 70. Direct Comparison with Distribution Share
Figure 71. Distributors Profiles
Figure 72. Years Considered
Figure 73. Research Process
Figure 74. Key Executives Interviewed
Scope & coverage.
Types
- Oligonucleotide Drugs
- Peptide Drugs
Applications
- Oncology Drugs
- Digestive system Drugs
- Immunomodulatory Drugs
- Bone and Connective Tissue Types
- Other
Companies covered
- Takeda
- Sanofi
- Novartis
- Roche
- Lilly
- SciClone Pharmaceuticals
- Sarepta Therapeutics
- Nippon Shinyaku
- Moderna
- MiNA Therapeutics
- Merck Serono
- Ipsen PHarma Biotech
- Ionis
- Ferring Pharmaceuticals
- BioNTech
- AstraZeneca
- Asahi Kasei
- Alnylam
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Peptide and Oligonucleotide Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Peptide and Oligonucleotide Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Peptide and Oligonucleotide Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Peptide and Oligonucleotide Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Peptide and Oligonucleotide Drugs Market Dynamics
- 2.1 Peptide and Oligonucleotide Drugs Industry Trends
- 2.2 Peptide and Oligonucleotide Drugs Industry Drivers
- 2.3 Peptide and Oligonucleotide Drugs Industry Opportunities and Challenges
- 2.4 Peptide and Oligonucleotide Drugs Industry Restraints
3 Peptide and Oligonucleotide Drugs Market by Manufacturers
- 3.1 Global Peptide and Oligonucleotide Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Peptide and Oligonucleotide Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Peptide and Oligonucleotide Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Peptide and Oligonucleotide Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Peptide and Oligonucleotide Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Peptide and Oligonucleotide Drugs Manufacturers, Product Type & Application
- 3.7 Global Peptide and Oligonucleotide Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Peptide and Oligonucleotide Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Peptide and Oligonucleotide Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Peptide and Oligonucleotide Drugs Tier 1, Tier 2, and Tier 3
4 Peptide and Oligonucleotide Drugs Market by Type
- 4.1 Peptide and Oligonucleotide Drugs Type Introduction
- 4.1.1 Oligonucleotide Drugs
- 4.1.2 Peptide Drugs
- 4.2 Global Peptide and Oligonucleotide Drugs Sales by Type
- 4.2.1 Global Peptide and Oligonucleotide Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Peptide and Oligonucleotide Drugs Sales by Type (2021-2032)
- 4.2.3 Global Peptide and Oligonucleotide Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Peptide and Oligonucleotide Drugs Revenue by Type
- 4.3.1 Global Peptide and Oligonucleotide Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Peptide and Oligonucleotide Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Peptide and Oligonucleotide Drugs Revenue Market Share by Type (2021-2032)
5 Peptide and Oligonucleotide Drugs Market by Application
- 5.1 Peptide and Oligonucleotide Drugs Application Introduction
- 5.1.1 Oncology Drugs
- 5.1.2 Digestive system Drugs
- 5.1.3 Immunomodulatory Drugs
- 5.1.4 Bone and Connective Tissue Types
- 5.1.5 Other
- 5.2 Global Peptide and Oligonucleotide Drugs Sales by Application
- 5.2.1 Global Peptide and Oligonucleotide Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Peptide and Oligonucleotide Drugs Sales by Application (2021-2032)
- 5.2.3 Global Peptide and Oligonucleotide Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Peptide and Oligonucleotide Drugs Revenue by Application
- 5.3.1 Global Peptide and Oligonucleotide Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Peptide and Oligonucleotide Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Peptide and Oligonucleotide Drugs Revenue Market Share by Application (2021-2032)
6 Global Peptide and Oligonucleotide Drugs Sales by Region
- 6.1 Global Peptide and Oligonucleotide Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Peptide and Oligonucleotide Drugs Sales by Region (2021-2032)
- 6.2.1 Global Peptide and Oligonucleotide Drugs Sales by Region (2021-2026)
- 6.2.2 Global Peptide and Oligonucleotide Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Peptide and Oligonucleotide Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Peptide and Oligonucleotide Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Peptide and Oligonucleotide Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Peptide and Oligonucleotide Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Peptide and Oligonucleotide Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Peptide and Oligonucleotide Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Peptide and Oligonucleotide Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Peptide and Oligonucleotide Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Peptide and Oligonucleotide Drugs Revenue by Region
- 7.1 Global Peptide and Oligonucleotide Drugs Revenue by Region
- 7.1.1 Global Peptide and Oligonucleotide Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Peptide and Oligonucleotide Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Peptide and Oligonucleotide Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Peptide and Oligonucleotide Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Peptide and Oligonucleotide Drugs Revenue (2021-2032)
- 7.2.2 North America Peptide and Oligonucleotide Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Peptide and Oligonucleotide Drugs Revenue (2021-2032)
- 7.3.2 Europe Peptide and Oligonucleotide Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Peptide and Oligonucleotide Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Peptide and Oligonucleotide Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Peptide and Oligonucleotide Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Peptide and Oligonucleotide Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Takeda
- 8.1.1 Takeda Company Information
- 8.1.2 Takeda Business Overview
- 8.1.3 Takeda Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Takeda Peptide and Oligonucleotide Drugs Product Portfolio
- 8.1.5 Takeda Recent Developments
- 8.2 Sanofi
- 8.2.1 Sanofi Company Information
- 8.2.2 Sanofi Business Overview
- 8.2.3 Sanofi Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Sanofi Peptide and Oligonucleotide Drugs Product Portfolio
- 8.2.5 Sanofi Recent Developments
- 8.3 Novartis
- 8.3.1 Novartis Company Information
- 8.3.2 Novartis Business Overview
- 8.3.3 Novartis Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Novartis Peptide and Oligonucleotide Drugs Product Portfolio
- 8.3.5 Novartis Recent Developments
- 8.4 Roche
- 8.4.1 Roche Company Information
- 8.4.2 Roche Business Overview
- 8.4.3 Roche Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Roche Peptide and Oligonucleotide Drugs Product Portfolio
- 8.4.5 Roche Recent Developments
- 8.5 Lilly
- 8.5.1 Lilly Company Information
- 8.5.2 Lilly Business Overview
- 8.5.3 Lilly Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Lilly Peptide and Oligonucleotide Drugs Product Portfolio
- 8.5.5 Lilly Recent Developments
- 8.6 SciClone Pharmaceuticals
- 8.6.1 SciClone Pharmaceuticals Company Information
- 8.6.2 SciClone Pharmaceuticals Business Overview
- 8.6.3 SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio
- 8.6.5 SciClone Pharmaceuticals Recent Developments
- 8.7 Sarepta Therapeutics
- 8.7.1 Sarepta Therapeutics Company Information
- 8.7.2 Sarepta Therapeutics Business Overview
- 8.7.3 Sarepta Therapeutics Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Sarepta Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio
- 8.7.5 Sarepta Therapeutics Recent Developments
- 8.8 Nippon Shinyaku
- 8.8.1 Nippon Shinyaku Company Information
- 8.8.2 Nippon Shinyaku Business Overview
- 8.8.3 Nippon Shinyaku Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Nippon Shinyaku Peptide and Oligonucleotide Drugs Product Portfolio
- 8.8.5 Nippon Shinyaku Recent Developments
- 8.9 Moderna
- 8.9.1 Moderna Company Information
- 8.9.2 Moderna Business Overview
- 8.9.3 Moderna Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Moderna Peptide and Oligonucleotide Drugs Product Portfolio
- 8.9.5 Moderna Recent Developments
- 8.10 MiNA Therapeutics
- 8.10.1 MiNA Therapeutics Company Information
- 8.10.2 MiNA Therapeutics Business Overview
- 8.10.3 MiNA Therapeutics Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 MiNA Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio
- 8.10.5 MiNA Therapeutics Recent Developments
- 8.11 Merck Serono
- 8.11.1 Merck Serono Company Information
- 8.11.2 Merck Serono Business Overview
- 8.11.3 Merck Serono Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Merck Serono Peptide and Oligonucleotide Drugs Product Portfolio
- 8.11.5 Merck Serono Recent Developments
- 8.12 Ipsen PHarma Biotech
- 8.12.1 Ipsen PHarma Biotech Company Information
- 8.12.2 Ipsen PHarma Biotech Business Overview
- 8.12.3 Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Product Portfolio
- 8.12.5 Ipsen PHarma Biotech Recent Developments
- 8.13 Ionis
- 8.13.1 Ionis Company Information
- 8.13.2 Ionis Business Overview
- 8.13.3 Ionis Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Ionis Peptide and Oligonucleotide Drugs Product Portfolio
- 8.13.5 Ionis Recent Developments
- 8.14 Ferring Pharmaceuticals
- 8.14.1 Ferring Pharmaceuticals Company Information
- 8.14.2 Ferring Pharmaceuticals Business Overview
- 8.14.3 Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio
- 8.14.5 Ferring Pharmaceuticals Recent Developments
- 8.15 BioNTech
- 8.15.1 BioNTech Company Information
- 8.15.2 BioNTech Business Overview
- 8.15.3 BioNTech Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 BioNTech Peptide and Oligonucleotide Drugs Product Portfolio
- 8.15.5 BioNTech Recent Developments
- 8.16 AstraZeneca
- 8.16.1 AstraZeneca Company Information
- 8.16.2 AstraZeneca Business Overview
- 8.16.3 AstraZeneca Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.16.4 AstraZeneca Peptide and Oligonucleotide Drugs Product Portfolio
- 8.16.5 AstraZeneca Recent Developments
- 8.17 Asahi Kasei
- 8.17.1 Asahi Kasei Company Information
- 8.17.2 Asahi Kasei Business Overview
- 8.17.3 Asahi Kasei Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.17.4 Asahi Kasei Peptide and Oligonucleotide Drugs Product Portfolio
- 8.17.5 Asahi Kasei Recent Developments
- 8.18 Alnylam
- 8.18.1 Alnylam Company Information
- 8.18.2 Alnylam Business Overview
- 8.18.3 Alnylam Peptide and Oligonucleotide Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.18.4 Alnylam Peptide and Oligonucleotide Drugs Product Portfolio
- 8.18.5 Alnylam Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Peptide and Oligonucleotide Drugs Value Chain Analysis
- 9.1.1 Peptide and Oligonucleotide Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Peptide and Oligonucleotide Drugs Production Mode & Process
- 9.2 Peptide and Oligonucleotide Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Peptide and Oligonucleotide Drugs Distributors
- 9.2.3 Peptide and Oligonucleotide Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst